NCT05188170招募中1 期
Phase 1 Study of Niclosamide (ANA001) in Pediatric Patients With Relapsed and Refractory AML
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 16
- 试验地点
- 1
- 主要终点
- Dose-limiting toxicity
研究概览
简要总结
Protocol is designed to evaluate a niclosamide dose escalation scale in combination with cytarabine as a therapeutic modality for pediatric subjects with relapsed/refractory acute myeloid leukemia.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 2 Years 至 25 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •1. Prior morphologically-confirmed diagnosis of AML based on WHO Criteria
- •Has previously failed all available and suitable therapies for AML. Disease relapse or the presence of refractory disease after ≥ 2 cycles of intensive chemotherapy; or ≥ 4 cycles of non-intensive chemotherapy or hypomethylating agents (HMAs) must be documented by bone marrow (BM) examination demonstrating ≥ 5% blasts in the BM by morphology or ≥ 1% blasts by flow cytometry,
- •5% blasts in the peripheral blood (confirmed by flow cytometry, cytogenetics or FISH), ≥ 1% MRD
- •+ by flow cytometry, FISH, PCR or NGS, and not attributable to another cause (EXCEPTION: subjects with frank disease progression in the face of treatment with HMA with or without venetoclax will be considered eligible regardless of treatment cycles administered if they meet the other eligibility criteria). No prior treatment with niclosamide.
- •Age ≥ 2 and ≤ 30 years
- •Body surface area (BSA) ≤ 2.10 m2
- •, calculated per the Mostellar formula
- •Must be able to tolerate po or ng medications.
- •Performance status: Subject ≤ 16 years old: Lansky ≥ 50 Subject > 16 years old: Karnofsky ≥ 50%
- •Life expectancy of greater than 4 weeks
- •Platelets ≥ 10,000/mm3 (for subjects with platelets < 10,000/mm3 at baseline, platelet transfusion support is allowed)
- •Measured or calculated creatinine clearance
- •60 mL/min/1.73 m2 (by the Cockcroft-Gault method) within 14 days prior to treatment initiation
- •Total bilirubin ≤ 2.0 x institutional upper limit of normal (ULN) within 14 days prior to treatment initiation (EXCEPTION: Subjects with Gilbert's syndrome may be included if the total bilirubin is
- •3.0 x ULN)
- •SGOT (AST) ≤ 3.0 x ULN and SGPT (ALT)
- •3.0 x ULN within 14 days prior to treatment initiation
- •Patients must have received their last dose of anti-cancer therapy (chemotherapy, immunotherapy, targeted agents, radiotherapy or investigational therapy) at least 2 weeks or 3 half-lives prior to the start of study treatment, whichever is longer.
- •For patients who have received prior hematopoietic stem cell transplants (HSCT), no evidence of GvHD and must be > 60 days since the HSCT. HSCT recipients must have completed their last course of tacrolimus, cyclosporine, or mycophenolate > 4 weeks before initiation of niclosamide
- •Females of reproductive potential (WOCBP) must have a negative pregnancy test within 14 days prior to study treatment. WOCBP must agree to use adequate contraception (eg, hormonal or barrier methods of birth control; abstinence; sterilized partner) from date of consent through the treatment period, and for 30 days after completion of niclosamide administration
- •Men only: Men must agree to use adequate contraception (eg, hormonal or barrier methods of birth control; abstinence; sterilized partner) from date of consent through the treatment period, and for 30 days after completion of niclosamide administration
- •Ability to understand the purpose and risks of the study and the willingness to sign a written informed consent document containing an authorization to use protected health information (in accordance with national and local subject privacy regulations
排除标准
- •Received anticancer therapy (chemotherapy, immunotherapy, radiotherapy, or investigational therapy) within 2 weeks prior to starting study treatment. Administration of hydroxyurea 10 to 20 mg/kg/day PO (maximum 1000 mg PO BID) to control high WBC > 50 x 103
- •/mm3 is permitted at MD discretion (however, hydroxyurea should be stopped at least 24 hours prior to protocol therapy start).
- •Receiving any other investigational agents, including niclosamide.
- •Unresolved toxicities due to prior anticancer therapy, defined as not having resolved to Grade 0 or 1 (by CTCAE version 5 criteria), unless otherwise defined in the inclusion/exclusion criteria with the exception of alopecia
- •Acute promyelocytic leukemia (French-American-British Class M3-AML)
- •Known active central nervous system (CNS) leukemia; subjects can enroll on study if CNS disease can be cleared with intrathecal chemotherapy, in the judgement of the treating physician
- •Known congenital bleeding disorders, including but not limited to hemophilia
- •Known active uncontrolled systemic infection
- •Malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel, uncontrolled symptomatic inflammatory bowel disease or ulcerative colitis, or partial or complete bowel obstruction, at the time of study entry
- •Inability to receive administration of niclosamide in the available formulation(s)
- •Uncontrolled intercurrent illness including, but not limited to, uncontrolled active infection, or psychiatric illness/social situations that would limit compliance with study requirements
- •Lactating or pregnant female
- •Known active hepatitis C
研究组 & 干预措施
Niclosamide 250 mg/m2 /day divided BID
Experimental
干预措施: Niclosamide (Drug)
Niclosamide 500 mg/m2 /day divided BID
Experimental
干预措施: Niclosamide (Drug)
Niclosamide 1200 mg/m2 /day divided BID
Experimental
干预措施: Niclosamide (Drug)
Niclosamide 800 mg/m2 /day divided BID
Experimental
干预措施: Niclosamide (Drug)
结局指标
主要结局
Dose-limiting toxicity
时间窗: 30 days
Dose-limiting toxicities (DLTs) are defined as any events ≥ Grade 3 that are at least possibly, probably, or definitely related to niclosamide treatment
次要结局
- Efficacy of niclosamide treatment clinical response(8 weeks)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Niclosamide and Enzalutamide in Treating Patients With Castration-Resistant, Metastatic Prostate CancerCastration Levels of TestosteroneCastration-Resistant Prostate CarcinomaMetastatic Prostate CarcinomaRecurrent Prostate CarcinomaStage IV Prostate AdenocarcinomaNCT02532114University of Washington5
Unknown
2 期
Effectiveness of Niclosamide as Add-on Therapy to the Standard of Care Measures in COVID-19 ManagementCovid-19SARS PneumoniaNCT04753619University of Baghdad150
Unknown
1 期
To Evaluate Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of DWRX2003 Against COVID-19HealthyNCT04524052Daewoong Pharmaceutical Co. LTD.32
Unknown
1 期
To Evaluate the Safety, Tolerability and Pharmacokinetic Properties of DWRX2003COVID-19 PatientsNCT04592835Daewoong Pharmaceutical Co. LTD.24
已完成
1 期
Study of Idarubicin, Cytarabine, and Nivolumab in Patients With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)LeukemiaAcute Myeloid LeukemiaMyelodysplastic SyndromeNCT02464657M.D. Anderson Cancer Center44